

REVIEW

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *Mater. Adv.*, 2022,
3, 7185Received 14th April 2022,
Accepted 1st August 2022

DOI: 10.1039/d2ma00420h

rsc.li/materials-advances

Bacterial outer membrane vesicles and their functionalization as vehicles for bioimaging, diagnosis and therapy

Kaikai Xue, Lu Wang * and Jinyao Liu *

Bacterial outer membrane vesicles (OMVs) are spherical nanostructures spontaneously released from Gram-negative bacteria. Natural OMVs that are abundant in lipopolysaccharides, phospholipids, proteins, and nucleic acids have diverse biological functions including extracellular communication, transferring contents to host cells, and modulating immune responses, which are involved in multiple processes in human health. In addition to their native characteristics, functionalization of OMVs has sparked substantial biomedical applications due to their advantages of nanoscale size and the ability to carry a broad variety of payloads. In this review, we summarize the bioactivities of OMVs, including biogenesis, immunogenicity, and interactions with host cells, followed by a discussion on the strategies of utilizing functionalized OMVs as delivery vehicles for bioimaging, diagnosis, and therapy. Particularly, the applications of engineered OMVs as therapeutics to treat inflammatory bowel diseases and several types of cancer and also as vaccines to prevent infections have been elaborated. We also highlight the challenges and future perspectives of using OMVs for different biomedical applications. This work would inspire new thoughts on the development of innovative OMV-based biomedical nanomaterials through synthetic bioengineering and physicochemical modification.

1. Introduction

Bacterial outer membrane vesicles (OMVs), which are extracellular vesicles discharged from all types of Gram-negative bacteria during growth, have been studied for decades due to their roles in cell-to-cell communication, biofilm formation, pathogenesis and stress responses.^{1,2} OMVs were first

Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Institute of Molecular Medicine, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China. E-mail: jyliu@sjtu.edu.cn, luwang@shsmu.edu.cn



Kaikai Xue

Kaikai Xue received her bachelor's degree in Biological Engineering from Shanxi University in 2022 and she is currently pursuing PhD under the supervision of Prof. Jinyao Liu at the School of Medicine, Shanghai Jiao Tong University. Her research focuses on bacterial-based bioagents and cancer immunotherapy.



Lu Wang

Lu Wang is an Assistant Professor in the Institute of Molecular Medicine, School of Medicine, Shanghai Jiao Tong University (SJTU), China. She received her bachelor's degree in Biotechnology from Northwest A&F University in 2013 and PhD in Biology from the University of Science and Technology of China in 2019. Then she joined Prof. Jinyao Liu's group as a postdoctoral fellow at the School of Medicine, SJTU. Her research focuses on bacteria-associated cancer immunotherapy.

identified in the envelopes of *Vibrio cholera*³ and *Neisseria meningitidis*⁴ during their normal growth. Subsequently, the detection of OMVs in the cerebrospinal fluid of patients with meningococcal infection⁵ has revealed that OMVs may be associated with bacterial pathogenesis, which has attracted great attention to the functionalization of these vesicles. In the past decade, natural OMVs derived from both pathogenic and commensal bacteria have been verified to orchestrate the mucosal immune system and even distal tissues to broadly affect the therapeutic responses of human diseases, including tumors, gastrointestinal disorders, and metabolic syndrome.⁶ OMVs derived from bacterial outer membranes are spherical lipid bilayer nanostructures with a size ranging from approximately 20 to 250 nm.⁷ Notably, the structure of OMVs allows them to carry cargo molecules either on the surface or inside of OMVs *via* genetic engineering or chemical modification. Proteomic and biochemical analyses have disclosed that OMVs contain substantial biological substrates from parent bacteria, such as periplasmic and membrane-bound proteins, lipopolysaccharides (LPS), toxins, peptidoglycans (PG), DNA, RNA and enzymes.⁸ Based on the interaction of these bacterial pathogen-associated molecular patterns (PAMPs) with host pattern recognition receptors (PRRs), OMVs possess inherent adjuvanticity to provoke immune responses.⁹ Thus, OMVs have been developed for a variety of biomedical applications in drug delivery, diagnostics, cancer immunotherapy, vaccines, and others. In this review, we aim to provide a comprehensive understanding of the biological characteristics of OMVs and then introduce the interactions between OMVs and host cells, followed by highlighting the advances of OMVs in biomedical applications (Fig. 1).




Fig. 1 Schematic diagram of the advantages of OMVs, such as inherent adjuvanticity, spherical lipid bilayer nanostructure, delivery vehicle, distal transfer of cargo, and ability of entry into cells for biomedical applications.

2. Biogenesis of OMVs

Compared to Gram-positive species, Gram-negative bacteria possess a lipopolysaccharide-rich outer membrane located outside the thin PG layer.¹⁰ The formation of OMVs is a highly spontaneous and conserved process that requires the outward budding and fission of an outer membrane lacking membrane-peptidoglycan bonds.¹¹ In principle, OMVs can be obtained in a liquid bacterial culture without the addition of any foreign molecules. However, the spontaneous release of OMVs is insufficient, resulting in low yields.¹² Thus, methods capable of increasing OMV production are needed for practical biological applications. Although the information about the molecular mechanisms of their dynamic production and shedding is limited, crosslinks bridging the outer membrane to PG, the lipid composition dictating membrane fluidity, and the accumulation of misfolded molecules may play essential roles in the biogenesis of OMVs.¹³

In fact, these factors have demonstrated to be able to regulate the production of OMVs, depending on the species of bacteria. Several genetic mutations involved in crosslinks between the outer membrane and PG, such as the Tol-Pal system, outer membrane protein A (OmpA), and lipoprotein (Lpp), are closely associated with enhanced OMV production.^{14,15} For example, the Tol-Pal system, composed of YbgC, TolQ, TolA, TolR, TolB, Pal and YbgF proteins, exhibits a non-covalent interaction with the PG and is important for outer membrane invagination during OMV biogenesis in *Escherichia coli*.¹⁶ Mutations in each of the seven Tol-Pal components can substantially increase OMV production. Meanwhile, lipoprotein diacylglycerol transferase (Lgt) is required for lipidation and maturation of Lpp by catalyzing the acylation of



Jinyao Liu

Jinyao Liu is a full Professor in the Institute of Molecular Medicine, School of Medicine, Shanghai Jiao Tong University (SJTU), China. After receiving his PhD at SJTU in Materials Science and Engineering under the supervision of Prof. Deyue Yan, Jinyao joined Prof. Ashutosh Chilkoti's group in the Department of Biomedical Engineering at Duke University (2013–2015) and Prof. Robert Langer's laboratory in the Koch

Institute for Integrative Cancer Research at MIT (2015–2018) as a postdoc associate. His current research interests include oral delivery, bacterial-based bioagents, hydrogels, and nanomedicines. Jinyao's publications have been featured by MIT News, Nature Communications Editors' Highlights, Noteworthy Chemistry, Hunan TV, etc.



Lpp.¹⁷ The mutation of Lgt leads to lack of Lpp, which increases the cytoplasmic membrane fluidity and vesicle formation of *E. coli*.¹⁸ Furthermore, the removal of LPS with detergents, such as EDTA, is a traditional method to increase the vesicle release and has been widely used for scale up.¹⁹ Vesiculation levels also display temperature-dependent alteration, which is presumably modulated by membrane lipid dynamics.²⁰ Additionally, bacteria exposed to stress factors, such as antibiotics, ultraviolet radiation and oxidative stress, tend to increase bulging of the outer membrane to remove the misfolded proteins in periplasm and envelope.^{21–23} Similarly, the lack of nutrients, including metal ions, lysine and hemin, can also cause an overproduction of OMVs to obtain carbon or iron from the surrounding environment *via* carrying more degradative enzymes or transferrin-binding proteins, respectively.²⁴ Strikingly, in addition to yields, the cargo of OMVs can also be regulated by environments. For example, under iron-limiting growth conditions, OMVs produced by *Helicobacter pylori* reduce the expressions of virulence factors, such as VacA, whereas they increase the expressions of proteolytic enzymes.²⁵ The polysaccharide portion of *Porphyromonas gingivalis* allows gingivalase to be preferentially packaged into OMVs and selectively excludes the outer membrane proteins RagA and RagB from OMVs.^{26,27} Collectively, different approaches have been utilized to increase the yields of OMVs, basing on the requirement for a given component or application and a specific bacterial strain.

3. Mechanisms of OMVs entry into host cells

Mucosal tissues, including the gastrointestinal tract, respiratory tract, and reproductive tract, represent the major barrier

between the host and the external environment. Particularly, the mucosal epithelial layer, forming a contiguous interface, is the first line of the barrier between the luminal contents and the host.²⁸ A number of studies have reported that OMVs released from various commensal or pathogenic bacteria in the lumina either maintain or disrupt host homeostasis by direct entry into mucosal epithelial cells.²⁹ In addition, OMVs can also cross the mucosal barrier through paracellular and trans-epithelial pathways to interact with myeloid cell subsets and further modulate immune responses. The entry of OMVs into different types of host cells can occur *via* multiple endocytic routes (Fig. 2), including micropinocytosis, lipid raft-mediated uptake, clathrin- and caveolin-mediated endocytosis, and PRR recognition.³⁰

Vesicles released from *Pseudomonas aeruginosa*,³¹ *P. gingivalis*,³² *Haemophilus influenza*,³³ and *Campylobacter jejuni*³⁴ enter gastric and airway epithelial cells through cholesterol-dependent fusion with lipid rafts, which is the most frequently reported route. While OMVs released by enterohemorrhagic *E. coli* (EHEC),³⁵ *H. pylori*,³⁶ and *Brucella abortus*³⁷ are internalized by epithelial cells or macrophage *via* clathrin-dependent, cholesterol-independent endocytosis. Vanaja *et al.* have provided the evidence that adaptor protein 2 (AP2) is probably involved in clathrin-mediated endocytosis, in which macrophage treated with EHEC-derived OMVs after the knockdown of AP2 display decreased internalization and alleviated inflammatory responses.³⁸ It is noted that the size and composition of OMVs appear to affect the route of the cell entry. For example, smaller OMVs (20–100 nm in diameter) from *H. pylori* preferentially enter epithelial cells *via* clathrin-mediated endocytosis, whereas larger OMVs (90–450 nm in diameter) enter these cells *via* micropinocytosis.³⁹ For the effect of composition, LPS with an intact O antigen guides *E. coli*-derived OMVs to enter HeLa cells *via* lipid raft-mediated endocytosis, yet the deficiency of




Fig. 2 Schematic diagram of different routes of OMVs to enter host cells, including micropinocytosis, lipid raft-mediated uptake, clathrin- and caveolin-mediated endocytosis, and extracellular PRRs.



the O antigen causes clathrin-mediated endocytosis.⁴⁰ Moreover, *Moraxella catarrhalis* produces OMVs that interact with Toll-like receptor 2 (TLR2) and subsequently enter alveolar epithelial cells to induce the chronic obstructive pulmonary disease.⁴¹ It is indicated that extracellular PRRs participate in modulating the entry of OMVs into host cells, although the mechanism remains unclear. Together, the capacity of OMVs to enter cells enables them to serve as delivery vehicles to transfer cargo into eukaryotic cells for different applications.

4. Immunogenicity of OMVs

Since OMVs contain multiple MAMPs, including LPS, lipoproteins, PG, flagellin, DNA, and RNA, it is presumable that the recognition and uptake of OMVs can engage with the host PRRs to trigger innate and adaptive immune responses.^{42,43} There are several types of PRRs, such as Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), NOD-like receptors (NLRs), and cytosolic sensors of DNA, which recognize individual PAMPs.⁴⁴ Given that the content and composition of OMVs depends on bacterial species, PRR signaling pathways induced by OMVs are different.

LPS, a large glycolipid molecule and composed of the lipid A, core oligosaccharide, and O antigen, is one of the most potent and classical PAMP.⁴⁵ The LPS binding protein delivers LPS from OMVs to CD14 on cell surfaces, where it is recognized by the TLR4-MD2 complex.^{46–48} Generally, OMVs produced by *E. coli*, *P. aeruginosa*, and *N. meningitidis* contain LPS and can effectively drive TLR4 dimerization, which recruits downstream adaptor molecules to mount an inflammatory response.^{49–51} OMVs derived from *P. aeruginosa* initiate the TLR adaptor myeloid differentiation primary response protein 88 (MyD88)-dependent nuclear factor-kappa B (NF- κ B) signaling pathway,⁵² whereas OMVs released from *H. pylori* activate the mitogen-activated protein kinase (MAPK) and activator protein 1 (AP-1) signaling pathway.⁵³ Specifically, upon uptake by macrophages, OMVs discharged from *P. aeruginosa*, *H. pylori*, *Neisseria gonorrhoeae*, and EHEC can activate inflammasome signaling, which causes the LPS-dependent secretion of inflammatory cytokines, mitochondrial apoptosis, and eventual cellular pyroptosis.^{54–56} Unlike pathogenic bacteria, *Bacteroides fragilis*, as a symbiotic strain, releases the capsular polysaccharide A (PSA) in OMVs to induce anti-inflammatory effects through TLR2 on the surface of dendritic cells (DCs), depending on the growth arrest and DNA-damage-inducible protein Gadd45 α .⁵⁷ Occasionally, multiple PRRs are simultaneously involved in the recognition of OMVs. For example, *M. catarrhalis*, one of the major respiratory tract pathogens in humans, indirectly releases OMV containing MID and unmethylated CpG-DNA motifs to activate host B cells via both TLR2 and TLR9.⁵⁸ Additionally, H7 flagellin of OMVs from EHEC O157 induces the interleukin 8 (IL-8) production via both TLR4 and TLR5 signaling in intestinal epithelial cells.⁵⁹

During the uptake of OMVs derived from *H. pylori*, *P. aeruginosa*, and *N. gonorrhoeae* by gastric epithelial cells, bacterial PG fragments are specifically recognized by nucleotide-

binding oligomerization domain (NOD) proteins NOD1 and NOD2 in the cytosol to activate NF- κ B.^{42,60,61} Intriguingly, certain components are deficient in OMVs compared to parent bacteria and hence allow them to activate different signaling pathways than their parent bacteria. For example, TLR13 recognizing bacterial ribosomal RNA is involved in bacteria-mediated innate responses but not in OMVs, owing to the absence of ribosomal RNA.⁶² Generally, OMV-mediated PRR signal transduction can also induce host epithelial cells to produce antimicrobial peptides, thereby promoting the clearance of pathogenic bacteria.³⁰ Furthermore, protein glycosylation is an emerging field to study bacterial virulence and pathogenicity. It has been reported that the N-linked protein glycosylation of *C. jejuni*, as the most abundant post-translation modification of proteins, plays an important role in intestinal adhesion, colonization and invasion.⁶³ OMVs generated by *C. jejuni* have been identified with 16 glycoproteins via proteomic analysis, which may be involved in the mechanism of OMV-host cell interaction.³⁴ In short, the diversified PRRs are mainly responsible for OMVs to launch innate immune responses and shape adaptive immune responses to specific pathogens.

5. Functionalized OMVs as delivery vehicles

As OMVs are resistant to degradation by various enzymes, they can be transported over long distances and can reach target sites. Meanwhile, by virtue of rapid detection and internalization by host cells, OMVs have been extensively developed as delivery vehicles to transport substances for different biomedical applications.⁶⁴ To date, a couple of methods have been used for loading various substances into OMVs (Fig. 3), such as genetic engineering, incubation, electroporation, membrane fusion and chemical modification.

First, genetic engineering is the most widely used approach to load desired proteins to either the exterior or interior of OMVs by transforming plasmids into parent bacteria. In this way, sophisticated anchor points are essential for protein location. For example, SlyB, sorted into the periplasmic side of the bacterial outer membrane by its N-terminus lipid moiety, is a native and conserved Lpp in Gram-negative bacteria.⁶⁵ Nanoluciferase (Nluc) is a small, highly stable, and ATP-independent bioluminescent protein, relying on its substrate to produce extremely robust luminescence.⁶⁶ It can be loaded within OMVs by co-expression with the SlyB protein in the parent bacteria. To enhance the targeting ability of OMVs, the SpyCatcher/Tag or SnoopCatcher/Tag system has been applied to display the functional cargo on the vesicle surface.^{67,68} Kim *et al.* have suggested that a single chain Fv antibody fragment can be successfully displayed on the OMV surface by creating a chimeric ClyA fusion protein.⁶⁹ Cheng *et al.* have also established a flexible “Plug-and-Display” platform in which antigen-tag can spontaneously bind to the protein catcher expressed in fusion with ClyA on the OMV membrane to simultaneously display multiple tumor antigens (Fig. 4).⁷⁰






Fig. 3 Schematic illustration of using different strategies to load cargo molecules into OMVs, including genetic engineering, direct co-incubation, electroporation, membrane fusion, and chemical modification.

Furthermore, it seems that incubating OMVs or parent cells with cargo to obtain drug-loaded OMVs represents a simple loading strategy. In previous studies, OMVs have been directly incubated with chemotherapeutic drugs or NIR dyes, followed by the removal of the free cargo through ultracentrifugation to carry payloads.^{71,72} The cargo can be alternatively incubated with the parent bacteria during the growth phase. In this case, substances can be engulfed by bacteria and sorted into OMVs through shedding, which is often applied for antibiotic loading, such as ceftriaxone, amikacin, azithromycin, ampicillin, levofloxacin, ciprofloxacin, and norfloxacin.⁷³ Interestingly, direct incubation with OMVs is incapable of loading antibiotics, which is probably ascribed to the drug efflux mechanism of live bacteria.⁷⁴ Electroporation is a nucleic acid delivery technique that employs short high-voltage pulses to form transient pores in biological membranes for the entry of substances. This technique recently has been used to promote the loading of siRNA and gold nanoparticles into OMVs without disrupting membrane integrity.⁷⁵ It is well-known that eukaryotic cell fusion relying on the structure of lipid bilayers is a general process, which induces changes in the cellular phenotype or function. Similarly, the aggregation and fusion of different types of OMVs induced by electrolytes or low pH can introduce exogenous antigens and generate new functions.⁷⁶ Sonication and physical extrusion have been frequently reported as efficient methods to prepare fused OMVs.⁷⁷ However, this method is occasionally suffering from membrane disruption, leading to disastrous leakage of cytoplasmic contents in OMVs.

Additionally, abundant lipids and proteins on the OMV surface provide opportunities to anchor cargo molecules through chemical modifications including covalent binding and non-covalent binding. Indeed, due to the similar composition of DSPE to phospholipids of OMV membranes, the RGD peptide, as a targeting ligand, can be readily inserted into OMV membranes using DSPE as a lipid head.⁷¹ In another study, Qing *et al.* have utilized calcium phosphate (CaP) to encapsulate OMVs, in which the acidic residues on the OMV surface offer the “nucleation sites” to chelate calcium ions.⁷⁸ Furthermore, different approaches can be cooperated to decorate OMVs for introducing multiple functions. For instance, OMVs derived from *E. coli* can be conjugated with maleimide (Mal) groups on the surface by a coupling reaction between the amines associated with membrane proteins of OMVs and NHS ester in Mal-PEG4-NHS.⁷⁹ Upon NIR irradiation, Mal groups on OMVs can form stable thioether bonds with the released tumor antigens in the tumor site, which promotes antigen uptake by DCs. Simultaneously, Mal functionalized OMVs are interiorly loaded with an inhibitor of indoleamine 2,3-dioxygenase (IDO), which is an immune suppressive checkpoint, *via* electroporation to enhance the efficacy of immune modulation. Taken together, various loading strategies have been explored to load cargo molecules into OMVs, which paves the way for their applications in a variety of biomedical applications.

6. Application of engineered OMVs for bioimaging and diagnosis

Bioimaging techniques play an important role in guiding the early diagnosis and treatment of diseases.⁸⁰ Exogenous bioimaging probes, which provide a visual signal with an optical, a magnetic or a nuclear method, can be designed and anchored onto OMVs (Fig. 5). Benefiting from this characteristic, it is feasible to examine OMV-mediated communication mechanisms between bacteria and hosts.

For instance, DiR iodide is a lipophilic fluorescent dye and widely used to label membranes. By labeling OMVs with DiR, Liu *et al.* have demonstrated that OMVs secreted from *Akkermansia muciniphila* can enter and accumulate in bone tissues to generate protective effects *via* augmenting osteogenic activity and inhibiting osteoclast formation.⁸¹ However, lipophilic fluorescent dyes *via* non-covalent binding are unstable and can be rapidly quenched to lost fluorescence emission. It is necessary to design and anchor bioimaging probes inside OMVs, which weaken fluorescence quenching and reduce leakage during systemic circulation. Based on this point, Chen *et al.* have developed a modular platform for biosensing applications by simultaneously modifying the interior and exterior of OMVs.⁶⁵ Leveraging the principle that SlyB is localized at the inner side of the outer membranes, Nluc can be loaded into OMVs through fusion with SlyB. Luminescence signals emitted from engineered OMVs containing SlyB-Nluc are highly visible both *in vitro* and *in vivo*. It is worth noting that a trivalent Scaf3






Fig. 4 Bioengineered OMVs as a versatile antigen display platform for tumor therapy. (a) Schematic illustration of OMV-mediated Plug-and-Display technology. Briefly, SpyCatcher (SpC)/SnoopCatcher (SnC) fused to ClyA on the OMV surface can conjugate to SpyTag (SpT)/SnoopTag (SnT)-tagged antigens via SpC–SpT or SnC–SnT binding, respectively. (b) Recording of tumor volume changes over time after different treatments. (c) Monitoring of survival rates in tumor-bearing mice after treatments. Copyright© 2021, Springer Nature.




Fig. 5 Schematic illustration of the application of engineered OMVs for bioimaging and diagnosis via (a and b) fluorescence or (c) optoacoustic approach.

scaffold is sandwiched between the ice nucleation protein (INP) anchor and the antibody-binding Z-domain for the modification of additional functional proteins, such as green fluorescent protein (GFP). These fluorescent OMVs are stabilized and extremely appropriate to explore the dysbiosis of commensal bacteria in digestive and airway systems as the lung commensal bacteria belonging to the genera *Bacteroides* and *Prevotella* have

been reported to promote pulmonary fibrosis through their OMVs.⁸²

In addition, bacterial vesicles can also be engineered for optoacoustic imaging (Fig. 6). Melanin, naturally synthesized in many organisms, is suitable for optoacoustic imaging given their broad optical absorption.⁸³ Via overexpressing tyrosinase in *E. coli*, a key enzyme in melanin synthesis, melanin can be






Fig. 6 OMVs derived from *E. coli* for optoacoustic imaging. (a) Schematic illustration of the production of melanin-loaded OMVs from *E. coli*. (b) Tumor accumulation in mice treated with PBS, OMV^{WT}, and OMV^{Mel}, respectively. The signals were monitored using a multispectral optoacoustic tomography (MSOT) system. Copyright© 2019, Springer Nature.

naturally packaged into OMVs, which generate an enhanced multi-spectral optoacoustic tomography signal and produce local heating upon irradiation.⁸⁴ After systemic administration, the engineered OMVs can accumulate in the tumor tissue of mice for both imaging and photothermal therapy. In line with this, polydopamine nanoparticles generated by oxidative polymerization of dopamine is a melanin-like material, which can be encapsulated into the OMV–cancer cell hybrid membrane for tumor-targeted photoacoustic imaging and photothermal therapy.⁸⁵ In general, these achievements indicate the potential of OMVs in bioimaging and disease diagnosis.

7. Application of OMVs for disease treatment

Given the inherent immunoregulatory properties and the ability to deliver exogenous antigens and therapeutic molecules,⁸⁶ either naturally produced or engineered bacterial OMVs have

been intensely applied as therapeutics for treating different diseases, such as inflammatory bowel disease (IBD) and tumors. OMVs have also been modified and used as vaccines to prevent bacterial and viral infections. In the following subsections, applications of OMVs for disease treatment are highlighted and discussed (Fig. 7).

7.1 IBD

IBD, including Crohn's disease (CD) and ulcerative colitis (UC), is characterized by chronic or recurring inflammation of intestines.⁸⁷ The breakdown of intestinal homeostasis maintained by the mucosal barrier and mucosal immunity is the key event in the pathogenesis of IBD.⁸⁸ Recently, substantial evidences have demonstrated the strong relationship between the gut microbiota and intestinal homeostasis.⁸⁹ OMVs derived from commensal bacteria are able to maintain intestinal homeostasis by interactions with intestinal epithelia and the mucosal immune system. For example, through releasing




Fig. 7 Schematic illustration of engineered bacterial OMVs for (a) enhancement of targeting, (b) delivery of therapeutics, (c) delivery of an immune checkpoint inhibitor, (d) promotion of safety, and (e and f) antigen delivery.



PSA-encapsulated OMVs, *B. fragilis* can be sensed by DCs through TLR2, thereby inducing the differentiation of IL-10-producing regulatory T cells (Tregs).^{57,86} It is well-known that Tregs, which are differentiated from CD4⁺ T cells, mainly participate in alleviated IBD by restraining inflammatory responses.⁹⁰ Treatment with OMVs from *B. fragilis* protects mice from intestinal inflammation and experimental colitis.⁹¹ In a similar fashion, OMVs derived from *Bacteroides thetaiotaomicron* significantly stimulate the IL-10 expression by colonic DCs in healthy individuals, but not in patients with CD or UC. The ability of *B. thetaiotaomicron*-derived OMVs to regulate immune responses enables them to be considered as prospective candidates for IBD therapy.⁹² *A. muciniphila*, a promising probiotic in the gut, plays an important role in the treatment of metabolic diseases. OMVs collected from *A. muciniphila* elevate the tight junction expression in epithelial cells and reduce the inflammation to increase the integrity of the intestinal barrier, which may rely on the amuc_1100, an outer membrane protein of *A. muciniphila*.⁹³ As expected, the oral administration of *A. muciniphila*-derived OMVs has shown protective effects in dextran sodium sulfate (DSS)-induced colitis.⁹⁴ In addition, compared with free antibiotics, OMV-carried antibiotics exhibit excellent intracellular delivery due to the advantages of OMVs in targeting and biocompatibility, thereby allowing the removal of intracellular bacteria.⁹⁵ Undisputedly, OMV-carried antibiotics are promising for fighting against the growing threat of antibiotic resistance in infectious diseases.

7.2 Tumors

OMVs possess the ability to accumulate in the tumor tissue through the enhanced permeability and retention (EPR) effect. Together with the innate immunogenicity, OMVs can be developed as a promising delivery platform to enhance the efficacy of immunotherapy. Melanoma is a malignant tumor locating in the basal layer of the epidermis and the dermis and characterized with rapid progression, fast relapse, and high metastasis.⁹⁶ As nanoscale OMVs are skin-permeable and can pass through the stratum corneum, they are appropriate drug delivery vehicles for melanoma therapy. Gao *et al.* have constructed the *E. coli* expressing TNF-related apoptosis inducing ligand (TRAIL) protein and modified the derived OMVs with the $\alpha\text{v}\beta 3$ integrin peptide, targeting ligand and indocyanine green for the targeted therapy of melanoma. The resulting multifunctional OMVs can induce transdermal photo-TRAIL-programmed treatment in skin melanoma to enhance antitumor performance.⁷² In addition, Tang *et al.* have modified attenuated *Salmonella* derived OMVs with the tumor-targeting ligand Arg-Gly-Asp (RGD) peptide to improve tumor-targeting ability. The modified OMVs have been further used to coat chemotherapy drug-loaded polymeric micelles to greatly improve the synergistic therapeutic efficacy of cancer immunotherapy. The systemic injection of OMVs can not only elicit effectively protective immunity to prevent the occurrence of melanoma, but also significantly inhibit the growth and metastasis of tumor and prolong the survival rate of tumor-bearing mice.⁷¹

Chen *et al.* have successfully synthesized the complex of gold nanoparticles and *E. coli*-derived OMVs. They have observed that the combination of this complex with radiotherapy significantly increases the intracellular reactive oxygen species (ROS) level, resulting in effective radio-sensitization and immunoactivation as well as successfully inhibited tumor growth in glioblastoma-bearing mice.⁹⁷ Other studies have shown that mixing attenuated *Klebsiella pneumoniae*-derived OMVs with chemotherapeutic DOX can induce an appropriate immune response, which effectively fight against lung cancer without significant toxicity *in vivo*.⁹⁸ Kim *et al.* have demonstrated the potential of bacterial OMVs to treat various cancers. The systemic administration of OMVs obtained from *E. coli* W3110 can accumulate in the tumor tissue and subsequently induce the interferon- γ (IFN- γ)-dependent antitumor effect. It is noted that despite OMVs are thought to initiate strong IFN- γ -mediated antitumor responses, IFN- γ paradoxically upregulates immunosuppressive factors, especially PD-L1 in the TME, which hamper the T-cell function and restrict the effectiveness of immunotherapeutics.⁹⁹ Based on this fact, Li *et al.* have genetically engineered attenuated *E. coli* to express the ectodomain of PD-1 on the surface (Fig. 8). OMVs collected from this bioengineered strain can bind with PD-L1 on the tumor cell surface and lead to the retarded tumor growth in the B16 or CT26 mouse model, which are attributed to the cooperation between immune stimulation and checkpoint inhibition.¹⁰⁰ Furthermore, Pan *et al.* have also extracted OMVs from *E. coli* which is modified with the tumor-targeting peptide Lyp1 and subsequently introduced the PD-1 plasmid into OMVs by electroporation. In this situation, the presence of Lyp1 guides the entry of these vesicles into tumor cells and subsequent release of the PD-1 plasmid to the nucleus. PD-1 overexpressed on the surface of tumor cells effectively binds to PD-L1, thereby blocking the PD-1/PD-L1 pathway and preventing immune escape. Simultaneously, OMVs recruit cytotoxic T lymphocytes and natural killer cells and induce the secretion of INF- γ to enhance antitumor immune responses.¹⁰¹ The immunosuppressive tumor microenvironment (TME) mediates immune tolerance and evasion in solid tumors, which reduces the efficacy of immunotherapy. By coating the OMV surface with a CaP shell, Qing *et al.* have developed a potent OMVbased strategy for reprogramming the immunosuppressive TME and enhancing cancer immunotherapy. The pHsensitive CaP shell can prevent the clearance of OMVs and decrease the toxicity of OMVs, facilitating the neutralization of acidic TME and the polarization of macrophages into the M1 type.⁷⁸ Although it has been extensively reported that OMVs play a crucial role in the treatment of different tumors, the fundamental understanding of the interface between OMVs and tumor cells or the immune system needs to be further investigated for applications in treating diverse tumors.

7.3 Vaccines

OMVs are mainly composed of bacterial outer membrane components, which inherently carry key antigenic substrates that are required to induce a protective immune response.






Fig. 8 Schematic illustration of tumor immunotherapy mediated by OMV-PD-1. Accumulation of PD-1-displaying OMVs at the tumor tissue increases the infiltration of DCs and natural killer cells by blocking the PD1/PD-L1 interaction. Copyright© 2020, American Chemical Society.

Different from live bacteria, inanimate OMVs are safe and moderately reactogenic and have been proposed as a vaccine strategy against bacterial pathogens shortly after their discovery. With the advances in genetic engineering and nanotechnology, OMVs with favorable safety, cost-effectiveness, and affordability have been developed as an ideal vaccine candidate to prevent epidemic diseases.¹⁰²

Meningococcal disease, caused by *N. meningitidis*, induces the infection and inflammation in both the brain and bloodstream. OMVs derived from the group B meningococci, well-known as Cuban vaccine, are the first OMV-based vaccine. Furthermore, they are also the first effective vaccine against the meningococcal disease worldwide, showing long-acting and high titers of bactericidal antibodies.¹⁰³ With the advance of genetic engineering, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have approved a multi-component type B meningococcal vaccine 4CMenB for the human use.¹⁰⁴ 4CMenB is a multi-component vaccine prepared by displaying three highly immunogenic antigens of fHbp, NadA, and NHBA on the surface of OMVs.¹⁰⁵ The combination of recombinant proteins and group B meningococci derived OMVs can trigger a strong bactericidal immune response against various serotype B isolates in adults, adolescents, and infants.¹⁰⁴ Although other OMV-based vaccines have not entered the clinical stage yet, prominent progress has been achieved in the past few years. For example, Shigella disease, also known as bacillary dysentery, is caused by *Shigella sonnei* from food, which leads to bacterial spreading and invasion in the intestinal epithelia and results in diarrhea.¹⁰⁶ Considering that the *S. sonnei* O-antigen polysaccharide is effective in stimulating the production of protective antibodies, Tian *et al.* have developed the O-antigen based OMV vaccine by expressing the O-antigen in recombinant *Salmonella* via the LPS synthesis pathway.¹⁰⁷ Inspired by this work, vaccines basing on polysaccharide antigen-loaded bacterial OMVs have received increasing attention. In addition, OMVs can also be

encapsulated in polyanhydride nanoparticles by a solvent displacement method using a copolymer of poly (methyl vinyl ether-co-maleic anhydride). Immunization with OMVs encapsulated in these nanoparticles by the nasal or oral route protects mice from traumatic *S. sonnei* infection.¹⁰⁸

In addition to bacterial infections, genetic engineering techniques and biomimetic nanotechnology allow OMVs to be manipulated to resist viral infections. For instance, the receptor binding domain (RBD) in the SARS-CoV-2 spike protein, which leads to viral invasion *via* specifically binding to angiotensin-converting enzyme 2 (ACE2) in host cells, is considered as an appealing subunit vaccine target. Zhang *et al.* have obtained envelop virus-mimetic hybrid membrane-derived vesicles (HNVs) by fusing the eukaryotic membrane vesicle overexpressing spike protein with OMVs. The HNVs present an intact antigen structure and enable to boost antiviral immune responses (Fig. 9).¹⁰⁹ Furthermore, Yang *et al.* have directly achieved the outward exposure of the fusion protein of ClyA-RBD on bacterial membranes and subsequently the presentation of the RBD on the vesicles using a high-pressure homogenization technology.¹¹⁰ Following the subcutaneous injection, these RBD-displaying OMVs can be accumulated in lymph nodes and elicit SARS-CoV-2-specific cellular and humoral immune responses in mice, which suggests the potential of using OMVs as a vaccine development platform.

8. Outlook

In recent years, the explorations of functionalized OMVs and their applications in biomedicine have increased continuously. OMVs possess a variety of unique properties, including a nanoscale structure, immunogenicity, and the ability to carry cargo molecules, which make them acquire high potential for bioimaging, diagnosis, and therapy. However, a few challenges remain before OMVs are ready for broad clinical applications.






Fig. 9 OMV-based virus-mimetic nanovaccines. (a) Schematic illustration of the preparation of virus-mimetic hybrid membrane-derived vesicles (HMs). (b) Flow cytometric analysis of spike protein-displayed CMVs (DiO, green), OMVs (Cy5.5, red), and HMs (yellow). (c) Kinetics of SARS-CoV-2 S1-specific IgG antibody titers in the serum. Copyright© 2022, Elsevier.

First, the mechanism of OMV generation has not been fully understood. Previous studies on OMVs have mainly focused on specific molecules related to their functions, which is beneficial for exploring potential biological applications. The explanation for the mechanism of OMV formation is primarily concentrated on several molecules, such as the Tol-Pal complex, mDAP, Lpp, and OmpA, whereas understanding the process of OMV generation can promote the development of artificial approaches for the directional modification of OMVs. To address this challenge, interdisciplinary collaboration is necessary for studying the mechanism of OMV generation. Second, isolation methods of OMVs are relatively limited. Currently, methods capable of separating OMVs can be mainly classified into two categories.¹¹¹ One is size-based separation, such as ultracentrifugation or size exclusion chromatography, which usually requires a large volume of samples and is time-consuming and susceptible to interference from other substrates with a similar size.¹¹² The other approach is based on the specific binding of OMVs to other substrates, such as immunomagnetic beads and polymer-based precipitation. Meanwhile, this separation method is not universal and may affect downstream analysis due to impurities introduced during the separation process. Therefore, it is pivotal to reveal the specific and ubiquitous markers for different OMVs through multi-omics data analysis. New methods that can efficiently isolate OMVs without affecting their native bioactivity are also an urgent need. Third, the presence of abundant endotoxin and virulence factors in OMVs,

especially LPS, largely restricts their clinical translation. Despite the genetic engineering technology has been used to develop endotoxin-reduced OMVs, it is needed to further reduce endotoxin levels before clinical trials.¹¹³ To this end, more comprehensive investigation of virulence factors on OMVs is required to ensure safety. Lastly, compared to the complexity of genetic engineering, chemical modification has been widely employed to functionalize exosomes, but not OMVs. The utilization of covalent conjugation or supramolecular interactions to modify OMVs may facilitate the generation of functionalized OMV-based nanomaterials and expand a broad range of biomedical applications. We anticipate that this work would inspire the innovation of next-generation nanomedicines for disease diagnosis, prevention and treatment.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was financially supported by the National Key Basic Research Program (SQ2021YFA090162), the National Natural Science Foundation of China (21875135), and the Innovative Research Team of High-Level Local Universities in Shanghai (SHSMU-ZDCX20210900).



References

- 1 C. Schwechheimer and M. J. Kuehn, *Nat. Rev. Immunol.*, 2015, **13**, 605–619.
- 2 M. D. Balhuizen, E. J. A. Veldhuizen and H. P. Haagsman, *Front. Microbiol.*, 2021, **12**, 629090.
- 3 S. N. Chatterjee and J. Das, *J. Gen. Microbiol.*, 1967, **49**, 1–11.
- 4 I. W. DeVoe and J. E. Gilchrist, *J. Exp. Med.*, 1973, **138**, 1156–1167.
- 5 I. W. DeVoe and J. E. Gilchrist, *J. Exp. Med.*, 1975, **141**, 297–305.
- 6 D. N. Villageliu and D. R. Samuelson, *Front. Microbiol.*, 2022, **13**, 828704.
- 7 Y. Tashiro, A. Inagaki, M. Shimizu, S. Ichikawa, N. Takaya, T. Nakajima-Kambe, H. Uchiyama and N. Nomura, *Biosci., Biotechnol., Biochem.*, 2011, **75**, 605–607.
- 8 A. T. Jan, *Front. Microbiol.*, 2017, **8**, 1053.
- 9 F. Mancini, O. Rossi, F. Necchi and F. Micoli, *Int. J. Mol. Sci.*, 2020, **21**, 4416.
- 10 T. J. Silhavy, D. Kahne and S. Walker, *Cold Spring Harb. Perspect. Biol.*, 2010, **2**, a000414.
- 11 M. Toyofuku, N. Nomura and L. Eberl, *Nat. Rev. Microbiol.*, 2019, **17**, 13–24.
- 12 Z. Zhu, F. Antenucci, K. R. Villumsen and A. M. Bojesen, *mBio*, 2021, **12**, e0170721.
- 13 E. D. Avila-Calderón, M. D. S. Ruiz-Palma, M. G. Aguilera-Arreola, N. Velázquez-Guadarrama, E. A. Ruiz, Z. Gomez-Lunar, S. Witonsky and A. Contreras-Rodríguez, *Front. Microbiol.*, 2021, **12**, 557902.
- 14 Y. Ojima, T. Sawabe, K. Konami and M. Azuma, *Biotechnol. Bioeng.*, 2020, **117**, 701–709.
- 15 F. Berlanda Scorza, A. M. Colucci, L. Maggiore, S. Sanzone, O. Rossi, I. Ferlenghi, I. Pesce, M. Caboni, N. Norais, V. Di Cioccio, A. Saul and C. Gerke, *PLoS One*, 2012, **7**, e35616.
- 16 H. Hirakawa, K. Suzue and H. Tomita, *Vaccines*, 2022, **10**, 422.
- 17 S. Payen, D. Roy, A. Boa, M. Okura, J. P. Auger, M. Segura and M. Gottschalk, *Microorganisms*, 2021, **9**, 2386.
- 18 A. Mychack and A. Janakiraman, *J. Bacteriol.*, 2021, **203**, e00640.
- 19 R. Acevedo, S. Fernández, C. Zayas, A. Acosta, M. E. Sarmiento, V. A. Ferro, E. Rosenqvist, C. Campa, D. Cardoso, L. Garcia and J. L. Perez, *Front. Immunol.*, 2014, **5**, 121.
- 20 P. Briaud, A. Frey, E. C. Marino, R. A. Bastock, R. E. Zielinski, R. E. Wiemels, R. A. Keogh, E. R. Murphy, L. N. Shaw and R. K. Carroll, *mSphere*, 2021, **6**, e0067621.
- 21 M. Hadadi-Fishani, S. Najjar-Peerayeh, S. D. Siadat, M. Sekhavati and A. M. Mobarez, *Iran. J. Microbiol.*, 2021, **13**, 824–831.
- 22 V. Zarantonello, T. P. Silva, N. P. Noyma, J. P. Gamalier, M. M. Mello, M. M. Marinho and R. C. N. Melo, *Front. Microbiol.*, 2018, **9**, 272.
- 23 M. J. H. Gerritzen, R. H. W. Maas, J. van den Ijssel, L. van Keulen, D. E. Martens, R. H. Wijffels and M. Stork, *Microb. Cell Factories*, 2018, **17**, 157.
- 24 C. W. Choi, E. C. Park, S. H. Yun, S. Y. Lee, Y. G. Lee, Y. Hong, K. R. Park, S. H. Kim, G. H. Kim and S. I. Kim, *J. Proteome Res.*, 2014, **13**, 4298–4309.
- 25 J. I. Keenan and R. A. Allardyce, *Eur. J. Gastroenterol. Hepatol.*, 2000, **12**, 1267–1273.
- 26 P. D. Veith, Y. Y. Chen, D. G. Gorasia, D. Chen, M. D. Glew, N. M. O'Brien-Simpson, J. D. Cecil, J. A. Holden and E. C. Reynolds, *J. Proteome Res.*, 2014, **13**, 2420–2432.
- 27 M. F. Haurat, J. Aduse-Opoku, M. Rangarajan, L. Dorobantu, M. R. Gray, M. A. Curtis and M. F. Feldman, *J. Biol. Chem.*, 2011, **286**, 1269–1276.
- 28 E. Izquierdo, J. Rodriguez-Coira, M. I. Delgado-Dolset, C. Gomez-Casado, D. Barber and M. M. Escribese, *J. Invest. Allergol. Clin. Immunol.*, 2022, **32**, 81–96.
- 29 D. Werling and T. W. Jungi, *Vet. Immunol. Immunopathol.*, 2003, **91**, 1–12.
- 30 M. Kaparakis-Liaskos and R. L. Ferrero, *Nat. Rev. Immunol.*, 2015, **15**, 375–387.
- 31 S. J. Bauman and M. J. Kuehn, *BMC Microbiol.*, 2009, **9**, 26.
- 32 N. Furuta, K. Tsuda, H. Omori, T. Yoshimori, F. Yoshimura and A. Amano, *Infect. Immun.*, 2009, **77**, 4187–4196.
- 33 S. W. Sharpe, M. J. Kuehn and K. M. Mason, *Infect. Immun.*, 2011, **79**, 4361–4369.
- 34 A. Elmi, E. Watson, P. Sandu, O. Gundogdu, D. C. Mills, N. F. Inglis, E. Manson, L. Imrie, M. Bajaj-Elliott, B. W. Wren, D. G. Smith and N. Dorrell, *Infect. Immun.*, 2012, **80**, 4089–4098.
- 35 M. Bielaszewska, C. Rüter, L. Kunsmann, L. Greune, A. Bauwens, W. Zhang, T. Kuczius, K. S. Kim, A. Mellmann, M. A. Schmidt and H. Karch, *PLoS Pathog.*, 2013, **9**, e1003797.
- 36 A. Olofsson, L. Nygård Skalmann, I. Obi, R. Lundmark and A. Arnqvist, *mBio*, 2014, **5**, e00979.
- 37 J. J. Lee, D. G. Kim, D. H. Kim, H. L. Simborio, W. Min, H. J. Lee, M. Her, S. C. Jung, M. Watarai and S. Kim, *J. Biol. Chem.*, 2013, **288**, 28049–28057.
- 38 R. Pascolutti, V. Algisi, A. Conte, A. Raimondi, M. Pasham, S. Upadhyayula, R. Gaudin, T. Maritzen, E. Barbieri, G. Caldieri, C. Tordonato, S. Confalonieri, S. Freddi, M. G. Malabarba, E. Maspero, S. Polo, C. Tacchetti, V. Hauke, T. Kirchhausen, P. P. Di Fiore and S. Sigismund, *Cell Rep.*, 2019, **27**, 3049–3061.e3046.
- 39 L. Turner, N. J. Bitto, D. L. Steer, C. Lo, K. D'Costa, G. Ramm, M. Shambrook, A. F. Hill, R. L. Ferrero and M. Kaparakis-Liaskos, *Front. Immunol.*, 2018, **9**, 1466.
- 40 E. J. O'Donoghue, N. Sirisaengtaksin, D. F. Browning, E. Bielska, M. Hadis, F. Fernandez-Trillo, L. Alderwick, S. Jabbari and A. M. Krachler, *PLoS Pathog.*, 2017, **13**, e1006760.
- 41 V. Schaar, S. P. de Vries, M. L. Perez Vidakovic, H. J. Bootsma, L. Larsson, P. W. Hermans, A. Bjartell, M. Mörgelin and K. Riesbeck, *Cell. Microbiol.*, 2011, **13**, 432–449.
- 42 M. Kaparakis, L. Turnbull, L. Carneiro, S. Firth, H. A. Coleman, H. C. Parkington, L. Le Bourhis, A. Karrar, J. Viala, J. Mak, M. L. Hutton, J. K. Davies, P. J. Crack, P. J. Hertzog, D. J. Philpott, S. E. Girardin, C. B. Whitchurch and R. L. Ferrero, *Cell. Microbiol.*, 2010, **12**, 372–385.



- 43 M. J. Kuehn and N. C. Kesty, *Genes Dev.*, 2005, **19**, 2645–2655.
- 44 H. Kumar, T. Kawai and S. Akira, *Biochem. Biophys. Res. Commun.*, 2009, **388**, 621–625.
- 45 R. Di Guida, A. Casillo, J. M. Tomás, S. Merino and M. M. Corsaro, *Int. J. Mol. Sci.*, 2022, **23**, 1204.
- 46 L. Gu, R. Meng, Y. Tang, K. Zhao, F. Liang, R. Zhang, Q. Xue, F. Chen, X. Xiao, H. Wang, H. Wang, T. R. Billiar and B. Lu, *Shock*, 2019, **51**, 256–265.
- 47 D. M. Pilla, J. A. Hagar, A. K. Haldar, A. K. Mason, D. Degrandi, K. Pfeffer, R. K. Ernst, M. Yamamoto, E. A. Miao and J. Coers, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 6046–6051.
- 48 J. C. Santos, M. S. Dick, B. Lagrange, D. Degrandi, K. Pfeffer, M. Yamamoto, E. Meunier, P. Pelczar, T. Henry and P. Broz, *EMBO J.*, 2018, **37**, e98089.
- 49 T. N. Ellis, S. A. Leiman and M. J. Kuehn, *Infect. Immun.*, 2010, **78**, 3822–3831.
- 50 A. Zariri, J. Beskers, B. van de Waterbeemd, H. J. Hamstra, T. H. Bindels, E. van Riet, J. P. van Putten and P. van der Ley, *Infect. Immun.*, 2016, **84**, 3024–3033.
- 51 M. R. Mirlashari and T. Lyberg, *Med. Sci. Monit.*, 2003, **9**, Br316–Br324.
- 52 K. Zhao, X. Deng, C. He, B. Yue and M. Wu, *Infect. Immun.*, 2013, **81**, 4509–4518.
- 53 C. C. Allison, T. A. Kufer, E. Kremmer, M. Kaparakis and R. L. Ferrero, *J. Immunol.*, 2009, **183**, 8099–8109.
- 54 P. Deo, S. H. Chow, M. L. Han, M. Speir, C. Huang, R. B. Schittenhelm, S. Dhital, J. Emery, J. Li, B. T. Kile, J. E. Vince, K. E. Lawlor and T. Naderer, *Nat. Microbiol.*, 2020, **5**, 1418–1427.
- 55 J. D. Cecil, N. M. O'Brien-Simpson, J. C. Lenzo, J. A. Holden, W. Singleton, A. Perez-Gonzalez, A. Mansell and E. C. Reynolds, *Front. Immunol.*, 2017, **8**, 1017.
- 56 J. Yang, I. Hwang, E. Lee, S. J. Shin, E. J. Lee, J. H. Rhee and J. W. Yu, *Front. Immunol.*, 2020, **11**, 581165.
- 57 Y. Shen, M. L. Giardino Torchia, G. W. Lawson, C. L. Karp, J. D. Ashwell and S. K. Mazmanian, *Cell Host Microbe*, 2012, **12**, 509–520.
- 58 M. L. Vidakovic, J. Jendholm, M. Mörgelin, A. Månsson, C. Larsson, L. O. Cardell and K. Riesbeck, *PLoS Pathog.*, 2010, **6**, e1000724.
- 59 M. Bielaszewska, M. Marejková, A. Bauwens, L. Kunsmann-Prokscha, A. Mellmann and H. Karch, *Int. J. Med. Microbiol.*, 2018, **308**, 882–889.
- 60 M. A. Cañas, M. J. Fábrega, R. Giménez, J. Badia and L. Beldomà, *Front. Microbiol.*, 2018, **9**, 498.
- 61 B. Thay, A. Damm, T. A. Kufer, S. N. Wai and J. Oscarsson, *Infect. Immun.*, 2014, **82**, 4034–4046.
- 62 A. Hidmark, A. von Saint Paul and A. H. Dalpke, *J. Immunol.*, 2012, **189**, 2717–2721.
- 63 S. Abouelhadid, S. J. North, P. Hitchen, P. Vohra, C. Chintoan-Uta, M. Stevens, A. Dell, J. Cuccui and B. W. Wren, *mBio*, 2019, **10**, e00297.
- 64 J. Nicolás-Ávila, J. M. Adrover and A. Hidalgo, *Immunity*, 2017, **46**, 15–28.
- 65 Q. Chen, S. Rozovsky and W. Chen, *Chem. Commun.*, 2017, **53**, 7569–7572.
- 66 S. Yu, Z. Li, J. Li, S. Zhao, S. Wu, H. Liu, X. Bi, D. Li, J. Dong, S. Duan and B. D. Hammock, *Sens. Actuators B Chem.*, 2021, **336**, 129717.
- 67 H. B. van den Berg van Saparoea, D. Houben, M. I. de Jonge, W. S. P. Jong and J. Luirink, *Appl. Environ. Microbiol.*, 2018, **84**, e02567.
- 68 H. B. van den Berg van Saparoea, D. Houben, C. Kuijl, J. Luirink and W. S. P. Jong, *Front. Microbiol.*, 2020, **11**, 890.
- 69 J. Y. Kim, A. M. Doody, D. J. Chen, G. H. Cremona, M. L. Shuler, D. Putnam and M. P. DeLisa, *J. Mol. Biol.*, 2008, **380**, 51–66.
- 70 K. Cheng, R. Zhao, Y. Li, Y. Qi, Y. Wang, Y. Zhang, H. Qin, Y. Qin, L. Chen, C. Li, J. Liang, Y. Li, J. Xu, X. Han, G. J. Anderson, J. Shi, L. Ren, X. Zhao and G. Nie, *Nat. Commun.*, 2021, **12**, 2041.
- 71 Q. Chen, H. Bai, W. Wu, G. Huang, Y. Li, M. Wu, G. Tang and Y. Ping, *Nano Lett.*, 2020, **20**, 11–21.
- 72 L. H. Peng, M. Z. Wang, Y. Chu, L. Zhang, J. Niu, H. T. Shao, T. J. Yuan, Z. H. Jiang, J. Q. Gao and X. H. Ning, *Sci. Adv.*, 2020, **6**, eaba2735.
- 73 W. Huang, Q. Zhang, W. Li, M. Yuan, J. Zhou, L. Hua, Y. Chen, C. Ye and Y. Ma, *J. Controlled Release*, 2020, **317**, 1–22.
- 74 S. Fazal and R. Lee, *Pharmaceutics*, 2021, **13**, 1430.
- 75 V. Gujrati, S. Kim, S. H. Kim, J. J. Min, H. E. Choy, S. C. Kim and S. Jon, *ACS Nano*, 2014, **8**, 1525–1537.
- 76 Y. M. D. Gnopo, A. Misra, H. L. Hsu, M. P. DeLisa, S. Daniel and D. Putnam, *J. Colloid Interface Sci.*, 2020, **578**, 522–532.
- 77 R. Roberts, G. Moreno, D. Bottero, M. E. Gaillard, M. Fingerhann, A. Graieb, M. Rumbo and D. Hozbor, *Vaccine*, 2008, **26**, 4639–4646.
- 78 S. Qing, C. Lyu, L. Zhu, C. Pan, S. Wang, F. Li, J. Wang, H. Yue, X. Gao, R. Jia, W. Wei and G. Ma, *Adv. Mater.*, 2020, **32**, e2002085.
- 79 Y. Li, K. Zhang, Y. Wu, Y. Yue, K. Cheng, Q. Feng, X. Ma, J. Liang, N. Ma, G. Liu, G. Nie, L. Ren and X. Zhao, *Small*, 2022, **18**, e2107461.
- 80 H. Gu, H. Tang, P. Xiong and Z. Zhou, *Nanomaterials*, 2019, **9**, 130.
- 81 J. H. Liu, C. Y. Chen, Z. Z. Liu, Z. W. Luo, S. S. Rao, L. Jin, T. F. Wan, T. Yue, Y. J. Tan, H. Yin, F. Yang, F. Y. Huang, J. Guo, Y. Y. Wang, K. Xia, J. Cao, Z. X. Wang, C. G. Hong, M. J. Luo, X. K. Hu, Y. W. Liu, W. Du, J. Luo, Y. Hu, Y. Zhang, J. Huang, H. M. Li, B. Wu, H. M. Liu, T. H. Chen, Y. X. Qian, Y. Y. Li, S. K. Feng, Y. Chen, L. Y. Qi, R. Xu, S. Y. Tang and H. Xie, *Adv. Sci.*, 2021, **8**, 2004831.
- 82 D. Yang, X. Chen, J. Wang, Q. Lou, Y. Lou, L. Li, H. Wang, J. Chen, M. Wu, X. Song and Y. Qian, *Immunity*, 2019, **50**, 692–706.e697.
- 83 D. L. Longo, R. Stefania, S. Aime and A. Oraevsky, *Int. J. Mol. Sci.*, 2017, **18**, 1719.
- 84 V. Gujrati, J. Prakash, J. Malekzadeh-Najafabadi, A. Stiel, U. Klemm, G. Mettenleiter, M. Aichler, A. Walch and V. Ntziachristos, *Nat. Commun.*, 2019, **10**, 1114.



- 85 D. Wang, C. Liu, S. You, K. Zhang, M. Li, Y. Cao, C. Wang, H. Dong and X. Zhang, *ACS Appl. Mater. Interfaces*, 2020, **12**, 41138–41147.
- 86 Y. J. Yu, X. H. Wang and G. C. Fan, *Acta Pharmacol. Sin.*, 2018, **39**, 514–533.
- 87 G. Bouma and W. Strober, *Nat. Rev. Immunol.*, 2003, **3**, 521–533.
- 88 C. C. Bain and A. M. Mowat, *Immunol. Rev.*, 2014, **260**, 102–117.
- 89 J. L. Round and S. K. Mazmanian, *Nat. Rev. Immunol.*, 2009, **9**, 313–323.
- 90 J. B. Yan, M. M. Luo, Z. Y. Chen and B. H. He, *J. Immunol. Res.*, 2020, **2020**, 8813558.
- 91 S. Ahmadi Badi, S. H. Khatami, S. H. Irani and S. D. Siadat, *Cell J.*, 2019, **21**, 57–61.
- 92 L. Durant, R. Stentz, A. Noble, J. Brooks, N. Gicheva, D. Reddi, M. J. O'Connor, L. Hoyles, A. L. McCartney, R. Man, E. T. Pring, S. Dilke, P. Hendy, J. P. Segal, D. N. F. Lim, R. Misra, A. L. Hart, N. Arebi, S. R. Carding and S. C. Knight, *Microbiome*, 2020, **8**, 88.
- 93 L. Wang, L. Tang, Y. Feng, S. Zhao, M. Han, C. Zhang, G. Yuan, J. Zhu, S. Cao, Q. Wu, L. Li and Z. Zhang, *Gut*, 2020, **69**, 1988–1997.
- 94 C. S. Kang, M. Ban, E. J. Choi, H. G. Moon, J. S. Jeon, D. K. Kim, S. K. Park, S. G. Jeon, T. Y. Roh, S. J. Myung, Y. S. Gho, J. G. Kim and Y. K. Kim, *PLoS One*, 2013, **8**, e76520.
- 95 W. Huang, L. Meng, Y. Chen, Z. Dong and Q. Peng, *Acta Biomater.*, 2022, **140**, 102–115.
- 96 Y. R. Woo, S. H. Cho, J. D. Lee and H. S. Kim, *Int. J. Mol. Sci.*, 2022, **23**, 1813.
- 97 M. H. Chen, T. Y. Liu, Y. C. Chen and M. H. Chen, *Nanomaterials*, 2021, **11**, 1661.
- 98 K. Kuerban, X. Gao, H. Zhang, J. Liu, M. Dong, L. Wu, R. Ye, M. Feng and L. Ye, *Acta Pharm. Sin. B*, 2020, **10**, 1534–1548.
- 99 O. Y. Kim, H. T. Park, N. T. H. Dinh, S. J. Choi, J. Lee, J. H. Kim, S. W. Lee and Y. S. Gho, *Nat. Commun.*, 2017, **8**, 626.
- 100 Y. Li, R. Zhao, K. Cheng, K. Zhang, Y. Wang, Y. Zhang, Y. Li, G. Liu, J. Xu, J. Xu, G. J. Anderson, J. Shi, L. Ren, X. Zhao and G. Nie, *ACS Nano*, 2020, **14**, 16698–16711.
- 101 J. Pan, X. Li, B. Shao, F. Xu, X. Huang, X. Guo and S. Zhou, *Adv. Mater.*, 2022, **34**, e2106307.
- 102 Z. Kis, R. Shattock, N. Shah and C. Kontoravdi, *J. Biotechnol.*, 2019, **14**, e1800376.
- 103 G. V. Sierra, H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez and M. H. Terry, *NIPH Ann.*, 1991, **14**, 195–207; discussion 208–110.
- 104 D. Serruto, M. J. Bottomley, S. Ram, M. M. Giuliani and R. Rappuoli, *Vaccine*, 2012, **30**(Suppl. 2), B87–B97.
- 105 M. Pizza, V. Scarlato, V. Masignani, M. M. Giuliani, B. Aricò, M. Comanducci, G. T. Jennings, L. Baldi, E. Bartolini, B. Capocchi, C. L. Galeotti, E. Luzzi, R. Manetti, E. Marchetti, M. Mora, S. Nuti, G. Ratti, L. Santini, S. Savino, M. Scarselli, E. Storni, P. Zuo, M. Broeker, E. Hundt, B. Knapp, E. Blair, T. Mason, H. Tettelin, D. W. Hood, A. C. Jeffries, N. J. Saunders, D. M. Granoff, J. C. Venter, E. R. Moxon, G. Grandi and R. Rappuoli, *Science*, 2000, **287**, 1816–1820.
- 106 K. L. Kotloff, *Curr. Opin. Pediatr.*, 2022, **34**, 147–155.
- 107 H. Tian, B. Li, T. Xu, H. Yu, J. Chen, H. Yu, S. Li, L. Zeng, X. Huang and Q. Liu, *Appl. Environ. Microbiol.*, 2021, **87**, e0096821.
- 108 A. I. Camacho, J. M. Irache, J. de Souza, S. Sánchez-Gómez and C. Gamazo, *Vaccine*, 2013, **31**, 3288–3294.
- 109 M. Zhang, L. Wang, J. Liu and Y. Pang, *iScience*, 2022, **25**, 104490.
- 110 Z. Yang, L. Hua, M. Yang, S. Q. Liu, J. Shen, W. Li, Q. Long, H. Bai, X. Yang, Z. Ren, X. Zheng, W. Sun, C. Ye, D. Li, P. Zheng, J. He, Y. Chen, W. Huang, X. Peng and Y. Ma, *Nano Lett.*, 2021, **21**, 5920–5930.
- 111 J. Klimentová and J. Stulík, *Microbiol. Res.*, 2015, **170**, 1–9.
- 112 L. L. Yu, J. Zhu, J. X. Liu, F. Jiang, W. K. Ni, L. S. Qu, R. Z. Ni, C. H. Lu and M. B. Xiao, *BioMed Res. Int.*, 2018, **2018**, 3634563.
- 113 H. C. Watkins, C. G. Rappazzo, J. S. Higgins, X. Sun, N. Brock, A. Chau, A. Misra, J. P. B. Cannizzo, M. R. King, T. R. Maines, C. A. Leifer, G. R. Whittaker, M. P. DeLisa and D. Putnam, *Mol. Ther.*, 2017, **25**, 989–1002.

